Home Cart 0 Sign in  
X

[ CAS No. 825-56-9 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 825-56-9
Chemical Structure| 825-56-9
Chemical Structure| 825-56-9
Structure of 825-56-9 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 825-56-9 ]

Related Doc. of [ 825-56-9 ]

Alternatived Products of [ 825-56-9 ]

Product Details of [ 825-56-9 ]

CAS No. :825-56-9 MDL No. :MFCD00491613
Formula : C8H6N2O Boiling Point : -
Linear Structure Formula :- InChI Key :ZEOMRHKTIYBETG-UHFFFAOYSA-N
M.W : 146.15 Pubchem ID :13217
Synonyms :

Calculated chemistry of [ 825-56-9 ]

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 11
Fraction Csp3 : 0.0
Num. rotatable bonds : 1
Num. H-bond acceptors : 3.0
Num. H-bond donors : 0.0
Molar Refractivity : 39.73
TPSA : 38.92 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.26 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.81
Log Po/w (XLOGP3) : 1.31
Log Po/w (WLOGP) : 1.74
Log Po/w (MLOGP) : 1.35
Log Po/w (SILICOS-IT) : 2.0
Consensus Log Po/w : 1.64

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.25
Solubility : 0.831 mg/ml ; 0.00568 mol/l
Class : Soluble
Log S (Ali) : -1.73
Solubility : 2.73 mg/ml ; 0.0187 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -3.36
Solubility : 0.0636 mg/ml ; 0.000436 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.89

Safety of [ 825-56-9 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P301+P312-P302+P352-P304+P340-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 825-56-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 825-56-9 ]
  • Downstream synthetic route of [ 825-56-9 ]

[ 825-56-9 ] Synthesis Path-Upstream   1~3

  • 1
  • [ 825-56-9 ]
  • [ 51039-53-3 ]
YieldReaction ConditionsOperation in experiment
93%
Stage #1: With n-butyllithium In tetrahydrofuran; hexane at -70 - -65℃; for 2 h; Inert atmosphere
Stage #2: With bromine In tetrahydrofuran; hexane at -70 - -65℃; for 1 h;
To a 500 mL four neck flask was charged tetra hydrofuran (170 mL) and 4 (17.0 g, 0.1163 mol). The reactionmass was cooled to -65 to -70 °C under nitrogen atmospherewith stirring and added n-butyl lithium (60.66 mL, 2.3 M inn-hexane, 0.1395 mol) over a period of 1h, further reactionmass was stirred at same temperature for 1.0 h. Bromine(11.15 g, 0.1395 mol) was added slowly to reaction mass bymaintaining the reaction temperature -65 to -70 °C. Furtherstirred the reaction mass for 1.0 h. Reaction completion wasmonitored by TLC. Reaction mass was warmed to around -10 °C and quenched with 1.0 N HCl solution (100 mL). Reactionmass was warmed to room temperature, compoundwas extracted with ethyl acetate (2 x 100 mL). Combinedorganic layer was washed with water (1 x 100 mL) followedby brine (100 mL), dried over anhydrous sodium sulphateand concentrated to one volume stage. Compound was crystallizedusing petroleum ether to yield the title compound asoff white solid. (Yield: 24.3 g, 93 percent). 1H-NMR (400 MHz,DMSO-d6): δ 7.57-7.68 (m, 3H), 7.95-7.98 (m, 2H). MS(ESI) m/z: 226.0
Reference: [1] Letters in Drug Design and Discovery, 2013, vol. 10, # 8, p. 783 - 791
  • 2
  • [ 825-56-9 ]
  • [ 3004-42-0 ]
Reference: [1] Organic and Biomolecular Chemistry, 2017, vol. 15, # 39, p. 8276 - 8279
  • 3
  • [ 825-56-9 ]
  • [ 1483-31-4 ]
Reference: [1] European Journal of Organic Chemistry, 2015, vol. 2015, # 1, p. 77 - 80
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 825-56-9 ]

Aryls

Chemical Structure| 725-12-2

[ 725-12-2 ]

2,5-Diphenyl-1,3,4-oxadiazole

Similarity: 0.98

Chemical Structure| 25877-53-6

[ 25877-53-6 ]

2-Methyl-5-(p-tolyl)-1,3,4-oxadiazole

Similarity: 0.98

Chemical Structure| 2491-91-0

[ 2491-91-0 ]

2,5-Di-p-tolyl-1,3,4-oxadiazole

Similarity: 0.98

Chemical Structure| 852-38-0

[ 852-38-0 ]

2-([1,1-Biphenyl]-4-yl)-5-phenyl-1,3,4-oxadiazole

Similarity: 0.91

Chemical Structure| 2043-06-3

[ 2043-06-3 ]

2,5-Di([1,1'-biphenyl]-4-yl)-1,3,4-oxadiazole

Similarity: 0.91

Related Parent Nucleus of
[ 825-56-9 ]

Oxadiazoles

Chemical Structure| 725-12-2

[ 725-12-2 ]

2,5-Diphenyl-1,3,4-oxadiazole

Similarity: 0.98

Chemical Structure| 25877-53-6

[ 25877-53-6 ]

2-Methyl-5-(p-tolyl)-1,3,4-oxadiazole

Similarity: 0.98

Chemical Structure| 2491-91-0

[ 2491-91-0 ]

2,5-Di-p-tolyl-1,3,4-oxadiazole

Similarity: 0.98

Chemical Structure| 852-38-0

[ 852-38-0 ]

2-([1,1-Biphenyl]-4-yl)-5-phenyl-1,3,4-oxadiazole

Similarity: 0.91

Chemical Structure| 2043-06-3

[ 2043-06-3 ]

2,5-Di([1,1'-biphenyl]-4-yl)-1,3,4-oxadiazole

Similarity: 0.91